Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer

By H. Heneghan, N. Miller, A. Lowery, K. Sweeney, J. Newell, M. Kerin. Annals of Surgery, 2010

686 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma (2011, methodology): “By using quantitative RT-PCR (qRT-PCR), we assayed the vesicle pellets and the vesicle-poor supernatants for three well characterized circulating miRNAs: miR-16, miR-92a, and let-7a (1, 8, 24).”
MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer (2015, background): “[209] who found elevated miR-195 expression in the blood of only patients with BC.”
Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies (2011, methodology): “We used qRT-PCR to examine expression of 79 miRNAs reported as circulating solid tumor biomarkers in purified sub-populations of blood cells and in matched healthy donor plasma (9-13) (Fig.”
MicroRNAs in body fluids—the mix of hormones and biomarkers (2011, positive): “A prospective study reported that tumor-specific miRNAs such as miR-195 were detected and significantly altered in the circulation by using prospectively collected samples from 127 women, including 83 patients with breast cancer and 44 healthy age-matched controls”
miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis (2020, background): “High levels of miR-10b were also found in ER-negative breast cancer, indicating a poor disease outcome [126].”